Using polygenic risk scores of serum CRP and the design of Mendelian randomization, the genetic propensity to higher serum CRP was associated with a reduced risk of schizophrenia and prostate cancer, as well as an increased risk of chronic obstructive pulmonary disease. This evidence concerns the gene CRP and prostate carcinoma.